Scarica l'app Stockscreener
27.82
9.08%
-2.78
Dopo l'orario di chiusura:
28.01
0.19
+0.68%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TVTX Giù?
Forum
Previsione
Frazionamento azionario
Travere Therapeutics Inc Borsa (TVTX) Ultime notizie
How liquid is Travere Therapeutics Inc. stockJuly 2025 Sector Moves & Free Reliable Trade Execution Plans - mfd.ru
Travere Therapeutics (NASDAQ:TVTX) Stock Price Down 7.9%Should You Sell? - MarketBeat
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? - AOL.com
CEO Change: Will Travere Therapeutics Inc. stock benefit from green energy trends2025 Performance Recap & High Return Trade Opportunity Guides - mfd.ru
Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results - Bluefield Daily Telegraph
Travere Therapeutics (TVTX) Earnings Expected to Grow: Should You Buy? - Yahoo! Finance Canada
Is Travere Therapeutics Inc. stock heavily shortedJuly 2025 Pullbacks & Fast Gain Swing Trade Alerts - mfd.ru
Published on: 2026-02-12 19:23:57 - baoquankhu1.vn
Travere Therapeutics (TVTX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Travere Therapeutics at Guggenheim Summit: Confident in Strategic Path By Investing.com - Investing.com Canada
What’s the analyst consensus on Travere Therapeutics Inc.July 2025 Trade Ideas & Safe Swing Trade Setups - mfd.ru
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
161,988 Shares in Travere Therapeutics, Inc. $TVTX Acquired by Essex Investment Management Co. LLC - MarketBeat
Travere Therapeutics, Inc. (TVTX) Stock Analysis: Unveiling a 40.86% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Travere Therapeutics, Inc. $TVTX Shares Sold by Federated Hermes Inc. - MarketBeat
Penserra Capital Management LLC Buys Shares of 80,556 Travere Therapeutics, Inc. $TVTX - MarketBeat
Market Review: Is Travere Therapeutics Inc trading at a discountWeekly Trade Analysis & Low Risk Entry Point Guides - baoquankhu1.vn
Piper Sandler Raises Price Target for TVTX to $38.00 | TVTX Stoc - GuruFocus
Insider Selling: Travere Therapeutics (NASDAQ:TVTX) CFO Sells 1,745 Shares of Stock - MarketBeat
Technical Reactions to TVTX Trends in Macro Strategies - Stock Traders Daily
Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit - Business Wire
Travere Therapeutics (NASDAQ:TVTX) Insider Sells $57,301.59 in Stock - MarketBeat
Bank of America Securities Sticks to Its Buy Rating for Travere Therapeutics (TVTX) - The Globe and Mail
Travere Therapeutics (NASDAQ:TVTX) CEO Eric Dube Sells 100,087 Shares - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Insider Sells $234,797.20 in Stock - MarketBeat
Insider Selling: Travere Therapeutics (NASDAQ:TVTX) CFO Sells 7,242 Shares of Stock - MarketBeat
Insider Selling: Travere Therapeutics (NASDAQ:TVTX) CAO Sells 4,333 Shares of Stock - MarketBeat
William Rote Sells 12,446 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Insider Sells $230,461.00 in Stock - MarketBeat
Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Is Travere Therapeutics (TVTX) Facing a Credibility Test in Its Disclosure and Risk Narrative? - Yahoo Finance
Published on: 2026-02-01 07:00:12 - baoquankhu1.vn
Lisanti Capital Growth LLC Invests $3.10 Million in Travere Therapeutics, Inc. $TVTX - MarketBeat
TVTX ALERT: Investigation Launched into Travere Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Encourages Investors and Potential Witnesses to Contact Law Firm - GlobeNewswire
Travere Therapeutics: Filspari's FSGS Approval Chance Is Higher Than You Think - Seeking Alpha
Hussman Strategic Advisors Inc. Has $1 Million Stock Position in Travere Therapeutics, Inc. $TVTX - MarketBeat
TVTX INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Launches Investigation into Travere Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law Firm - The Malaysian Reserve
TVTX INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Laun - GuruFocus
Travere therapeutics CEO Dube sells $1.8 million in TVTX stock By Investing.com - Investing.com Canada
Travere Therapeutics (NASDAQ:TVTX) CEO Sells $244,131.35 in Stock - MarketBeat
Travere Therapeutics (TVTX) Stock Analysis: Exploring a 40% Upside in Rare Disease Biotechnology - DirectorsTalk Interviews
TVTX: Travere Therapeutics Shareholders Should Contact Block & Leviton To Potentially Recover Losses - GlobeNewswire
Universal Beteiligungs und Servicegesellschaft mbH Boosts Holdings in Travere Therapeutics, Inc. $TVTX - MarketBeat
BofA remains positive on Travere despite FDA decision delay for Filspari - MSN
Travere Therapeutics provides corporate update and 2026 outlook - MSN
Trading the Move, Not the Narrative: (TVTX) Edition - Stock Traders Daily
Palisades Investment Partners Acquires $5.26M Stake in Travere Therapeutics - intellectia.ai
Travere Therapeutics (TVTX) Hits Fresh High on Impressive Earnings, Bullish Outlook - MSN
Benign Growth For Travere Therapeutics, Inc. (NASDAQ:TVTX) Underpins Stock's 27% Plummet - simplywall.st
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):